Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at vinflunine chemotherapy for advanced bladder, kidney or ureter cancer (L00070 IN 302 P1)
This trial was comparing best
The urinary tract includes the
- Centre of the kidney (renal pelvis)
- Ureter – the tube that takes urine from the kidney to the bladder
Cancer that spreads to another part of the body is called advanced cancer. It is usually more difficult to treat. Doctors often give chemotherapy but sometimes the cancer continues to grow.
Some people have another course of chemotherapy (
Doctors thought that a chemotherapy drug called vinflunine might be useful for advanced urinary tract cancer. But they were not sure how well it would work.
The aim of this trial was to compare best supportive care and vinflunine with best supportive care alone, to see which was better as second line treatment for advanced urinary tract cancer.
Summary of results
The trial team found that on average, people who had vinflunine and best supportive care lived longer than people who had best supportive care alone.
The trial recruited 370 people who had already had other chemotherapy including a
- Two thirds had vinflunine and best supportive care
- One third had best supportive care alone
On average, people having vinflunine had 3 cycles of treatment. The side effects included a drop in the number of blood cells, fatigue, constipation, mild hair loss and reactions at the injection site. Although fatigue is a common side effect of chemotherapy, in this trial the researchers found that nearly 1 in 5 people having best supportive care alone also had fatigue.
The average length of time that people lived after treatment was more than 2 and a half months longer in the group who had vinflunine.
From these results, the researchers say that vinflunine could become a standard second line treatment for cancer of the urinary tract.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Prof Nick James
Pierre Fabre Medicament